Even though most NSCLC patients with EGFR mutations achieve an objective response (OR) to TKIs, 20–30% of patients still show disappointing outcomes after TKI treatment due to intrinsic resistance [7]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.